FAKEEH CARE

03 July, 2024 08:32

Dr. Soliman Abdel Kader Fakeeh Hospital Co. announces its Interim Financial results for the Period Ending on 2024-03-31 ( Three Months )

Element ListCurrent QuarterSimilar quarter for previous year%ChangePrevious Quarter% Change
Sales/Revenue 680.33529.4128.507662.322.719
Gross Profit (Loss) 188.58144.430.595163.3615.438
Operational Profit (Loss) 10784.1927.09395.9111.562
Net profit (Loss) 60.760.520.29763.11-3.818
Total Comprehensive Income 60.760.520.29755.98.586
All figures are in (Millions) Saudi Arabia, Riyals


Element ListCurrent PeriodSimilar period for previous year%Change
Total Shareholders Equity (after Deducting Minority Equity) 1,092.981,969.68-44.509
Profit (Loss) per Share 0.360.36
All figures are in (Millions) Saudi Arabia, Riyals


Element ListAmountPercentage of the capital (%)
Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value --
All figures are in (Millions) Saudi Arabia, Riyals


Element ListExplanation
The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the same quarter of the last year is Revenue in the current quarter increased by 28.5% to reach 680.3M from 529.4M in Q1 2023, driven by growing patient numbers in Jeddah and Riyadh, further supported by the Group's operate and manage (O&M) contract in NEOM.
The reason of the increase (decrease) in the net profit during the current quarter compared to the same quarter of the last year is Net profit in the current quarter increased by 0.3% to reach 60.7M from 60.5M in Q1 2023, with revenue growth being offset partly by higher finance charges, higher depreciation on additional investments and higher provisions for zakat. Net Profit in Q1 2023 also included a one-off finance income of 11.9M from a long-term receivable balance which was settled in September 2023. EBITDA in the current quarter increased by 10.7% to reach 144.5M from 130.6M in Q1 2023, reflecting strong revenue growth and optimized cost structure. EBITDA in Q1 2023 also included a one-off finance income of 11.9M from a long-term receivable balance which was settled in September 2023.
The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the previous one is Revenue reached 680.3M, higher by 2.7% from 662.3M of the preceding quarter due to stronger hospital census and increased activity within the O&M contract, despite the impact of seasonality.
The reason of the increase (decrease) in the net profit (loss) during the current quarter compared to the previous one is Net profit reached 60.7M, lower 3.8% from 63.1M in the preceding quarter as a result of increased finance charges and zakat provisions. EBITDA reached 144.5M, higher by 6.4% from 135.7M of the preceding quarter as a result of top-line growth reflecting in better operating profit.
Statement of the type of external auditor's report Unmodified conclusion
Comment mentioned in the external auditor’s report, mentioned in any of the following paragraphs (other matter, conservation, notice, disclaimer of opinion, or adverse opinion) NA
Reclassification of Comparison Items Yes
Additional Information NA
Attached Documents  

Other Announcements

UACC
2024-07-04

Umm Al-Qura Cement Company announces the appointment of the Chairman of the Board of Directors and its Vice Chairman, as well as the formation of the committees emanating from the board.

Read More
SARCO
2024-07-04

Addendum Announcement from Saudi Arabic Refineries Company Concerning Inviting its Shareholders to Attend the Extraordinary General Assembly Meeting (First Meeting)

Read More
AMAK
2024-07-04

Almasane Alkobra Mining Company (AMAK) announces the Expiration of its Acting CEO's Employment Contract and Appointment of an Acting CEO.

Read More